Episurf Medical approved supplier to BMI Healthcare, the largest independent hospital provider in the UK
Episurf Medical (NASDAQ: EPIS B) has become an approved supplier to BMI Healthcare, the largest independent hospital provider in the UK with 55 hospitals throughout the UK. The decision has been taken following a review process.
“We are very pleased that the Episealer®, with the support from some of our early customers and leading surgeons in the UK, has received approval from BMI Healthcare as a new treatment method for focal cartilage and bone lesions of the knee”, says Pål Ryfors, CEO Episurf Medical. “The UK market represents a highly attractive commercial opportunity for us. As we are preparing for further market penetration based on clinical evidence and expanded reimbursement and insurance coverage, it is highly encouraging to be approved as supplier to the largest private hospital group in the UK”, concludes Ryfors.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CEST on 1 July 2020.